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Association of Initial SARS-CoV-2 Test Positivity With Patient-Reported Well-being
3 Months After a Symptomatic Illness
Lauren E. Wisk, PhD; Michael A. Gottlieb, MD; Erica S. Spatz, MD, MHS; Huihui Yu, PhD; Ralph C. Wang, MD, MAS; Benjamin H. Slovis, MD, MA;
Sharon Saydah, PhD; Ian D. Plumb, MBBS, MSc; Kelli N. O’Laughlin, MD, MPH; Juan Carlos C. Montoy, MD, PhD; Samuel A. McDonald, MD, MS; Zhenqiu Lin, PhD;
Jin-Mann S. Lin, PhD; Katherine Koo, MS-HSM; Ahamed H. Idris, MD; Ryan M. Huebinger, MD; Mandy J. Hill, DrPH, MPH; Nicole L. Gentile, MD, PhD;
Anna Marie Chang, MD, MSCE; Jill Anderson, BSN, RN; Bala Hota, MD, MPH; Arjun K. Venkatesh, MD, MBA, MHS; Robert A. Weinstein, MD; Joann G. Elmore, MD, MPH;
Graham Nichol, MD, MPH; for the INSPIRE Group

Abstract

Key Points

IMPORTANCE Long-term sequelae after symptomatic SARS-CoV-2 infection may impact well-being,
yet existing data primarily focus on discrete symptoms and/or health care use.

Question How do patient-reported
physical, mental, and social well-being
compare at 3 months after symptomatic

OBJECTIVE To compare patient-reported outcomes of physical, mental, and social well-being
among adults with symptomatic illness who received a positive vs negative test result for SARS-

illness among those who tested positive
vs negative for SARS-CoV-2 infection?
Findings In this cohort study of 1000

CoV-2 infection.

US adults with symptomatic illness, poor

DESIGN, SETTING, AND PARTICIPANTS This cohort study was a planned interim analysis of an

well-being scores at follow-up were

ongoing multicenter prospective longitudinal registry study (the Innovative Support for Patients

common in both those who tested

With SARS-CoV-2 Infections Registry [INSPIRE]). Participants were enrolled from December 11, 2020,

positive and negative for SARS-CoV-2

to September 10, 2021, and comprised adults (aged ⱖ18 years) with acute symptoms suggestive of

infection. Despite some improvements

SARS-CoV-2 infection at the time of receipt of a SARS-CoV-2 test approved by the US Food and Drug

over time, 39.6% of COVID-19–positive

Administration. The analysis included the first 1000 participants who completed baseline and

and 53.5% of COVID-19–negative

3-month follow-up surveys consisting of questions from the 29-item Patient-Reported Outcomes

patients reported residual symptoms.

Measurement Information System (PROMIS-29; 7 subscales, including physical function, anxiety,
depression, fatigue, social participation, sleep disturbance, and pain interference) and the PROMIS
Short Form–Cognitive Function 8a scale, for which population-normed T scores were reported.

Meaning These findings emphasize the
importance of including a concurrent
control group when studying sequelae
of COVID-19 illness.

EXPOSURES SARS-CoV-2 status (positive or negative test result) at enrollment.
MAIN OUTCOMES AND MEASURES Mean PROMIS scores for participants with positive COVID-19
tests vs negative COVID-19 tests were compared descriptively and using multivariable regression
analysis.

+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

RESULTS Among 1000 participants, 722 (72.2%) received a positive COVID-19 result and 278
(27.8%) received a negative result; 406 of 998 participants (40.7%) were aged 18 to 34 years, 644
of 972 (66.3%) were female, 833 of 984 (84.7%) were non-Hispanic, and 685 of 974 (70.3%) were
White. A total of 282 of 712 participants (39.6%) in the COVID-19–positive group and 147 of 275
participants (53.5%) in the COVID-19–negative group reported persistently poor physical, mental, or
social well-being at 3-month follow-up. After adjustment, improvements in well-being were
statistically and clinically greater for participants in the COVID-19–positive group vs the COVID-19–
negative group only for social participation (β = 3.32; 95% CI, 1.84-4.80; P < .001); changes in other
well-being domains were not clinically different between groups. Improvements in well-being in the
COVID-19–positive group were concentrated among participants aged 18 to 34 years (eg, social
(continued)
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Abstract (continued)

participation: β = 3.90; 95% CI, 1.75-6.05; P < .001) and those who presented for COVID-19 testing
in an ambulatory setting (eg, social participation: β = 4.16; 95% CI, 2.12-6.20; P < .001).
CONCLUSIONS AND RELEVANCE In this study, participants in both the COVID-19–positive and
COVID-19–negative groups reported persistently poor physical, mental, or social well-being at
3-month follow-up. Although some individuals had clinically meaningful improvements over time,
many reported moderate to severe impairments in well-being 3 months later. These results highlight
the importance of including a control group of participants with negative COVID-19 results for
comparison when examining the sequelae of COVID-19.
JAMA Network Open. 2022;5(12):e2244486. doi:10.1001/jamanetworkopen.2022.44486

Introduction
Post–COVID-19 conditions (PCCs), often referred to as long COVID, are a heterogeneous group of
conditions generally referring to symptoms that emerge, recur, or persist for more than 4 weeks after
acute infection with SARS-CoV-2.1 Hallmarks of PCCs include fatigue, cognitive impairment, and
postexertional malaise along with symptoms encompassing nearly every organ system.2 Previous
literature suggests that up to one-half of those with SARS-CoV-2 infection experience persistent
symptoms more than 4 weeks after acute infection.3-6 Studies of PCCs have primarily described
discrete symptoms and/or health care use,3 with few addressing patient-reported outcomes such as
health-related quality of life.
Assessment of patient-reported outcomes after COVID-19 can provide a deeper understanding
of the patient experience and the ways in which the pandemic has impacted physical, mental, and
social well-being.7 Individuals who have experienced social isolation, work disruption, or
hospitalization during the pandemic might report similar impairments in well-being without
antecedent COVID-19 illness8,9; therefore, inclusion of a concurrent control group is important to
fully understand how well-being progresses after COVID-19. Well-established tools for measuring
well-being are the Patient-Reported Outcomes Measurement Information System (PROMIS)
instruments. These scales were developed and validated for the evaluation of patient-centric health
domains, such as pain, fatigue, physical functioning, sleep, and emotional distress, that have major
consequences for quality of life.10,11 The PROMIS instruments provide data on a prepandemic
population-standardized norm for these domains, which facilitates comparisons across groups and
against prepandemic expected values.
The Innovative Support for Patients With SARS-CoV-2 Infections Registry (INSPIRE) study was
designed to prospectively assess long-term outcomes of adults with symptomatic acute COVID-19
alongside contemporary controls comprising adults who had similar symptoms but tested negative
for SARS-CoV-2.12 In this interim analysis involving the first 1000 participants, we describe the
patient-reported outcomes of physical and mental well-being (measured by the 29-item PROMIS
[PROMIS-29] survey, version 2.1) and cognitive functioning (measured by the PROMIS Short Form–
Cognitive Function [PROMIS SF-CF] 8a survey) at baseline and 3-month follow-up among
participants with symptomatic illness who tested positive for COVID-19 vs those with symptomatic
illness who tested negative at initial enrollment. Individuals with symptomatic illness who tested
negative for SARS-CoV-2 infection were selected as the comparator group to identify the
consequences of infection specifically with SARS-CoV-2 (vs another virus) for changes in well-being.
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Methods
Study Design and Data Source
INSPIRE is an ongoing multicenter prospective longitudinal registry study enrolling individuals with
acute symptoms suggestive of COVID-19 in 8 sites across the US. Recruitment occurs in person, by
phone or email, and through online advertisement. A secure online platform (Hugo; Hugo Health
LLC) facilitates the collation of consent-related materials, linkage to participants’ electronic health
records, and responses to self-administered surveys. This study involved self-enrollment via an
online consent process using an electronic consent form implemented in the Hugo platform; all
included participants provided electronic informed consent. This study was approved by the
institutional review boards across 8 sites: Rush University (Chicago, Illinois), Yale University (New
Haven, Connecticut), the University of Washington (Seattle), Thomas Jefferson University
(Philadelphia, Pennsylvania), the University of Texas Southwestern Medical Center (Dallas),
UTHealth Houston (Houston, Texas), the University of California, San Francisco (San Francisco), and
the University of California, Los Angeles (Los Angeles). A detailed description of the study design has
been published.12 This study followed the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) reporting guideline for cohort studies.

Cohort Definition
This study included adult participants (aged ⱖ18 years) who were recently under clinical
investigation for SARS-CoV-2 infection, were fluent in English or Spanish, had self-reported
symptoms suggestive of acute SARS-CoV-2 infection (eAppendix in Supplement 1),13 and received
testing for SARS-CoV-2 infection with any molecular or antigen-based assay approved or authorized
by the US Food and Drug Administration within 42 days before enrollment. An individual was
ineligible if the study team was unable to confirm the result of a diagnostic test for COVID-19 or if the
individual was unable to provide informed consent, lacked access to an internet-enabled device or
computer that would allow for participation, had a SARS-CoV-2 infection more than 42 days before
enrolling in the study, or was imprisoned while participating in the study. The goal was to recruit
individuals at a 3:1 ratio of those with positive results for COVID-19 to those with negative results for
COVID-19.12
Participants were grouped based on their initial COVID-19 status (ie, COVID-19 positive or
negative at enrollment). If more than 1 COVID-19 test was performed within 7 days of enrollment and
results were discordant, we considered the positive test results to be the true measure. However, if
participants’ test positivity changed during the study (ie, later than 7 days after enrollment), we
retained them in their initial group following an intention-to-treat approach. In this cohort, 2 of 1000
participants (0.2%) converted from the COVID-19–negative group to the COVID-19–positive group
during the initial 3-month study period.
In this interim analysis, we included the first 1000 participants who completed the PROMIS
surveys12 at baseline and 3-month follow-up (Figure 1). Participants included in this analysis were
enrolled from December 11, 2020, to September 10, 2021.

Cohort Characteristics
Participants self-reported sociodemographic data at baseline, including age, gender (female; male;
or transgender, nonbinary, or other genders), ethnicity (Hispanic or non-Hispanic) or race (Asian,
Native Hawaiian, or other Pacific Islander; Black or African American; White; other race; or more than
1 race), educational level (less than high school diploma, high school or general educational
development diploma, some college but did not complete degree, 2-year college degree, 4-year
college degree, or more than 4-year college degree), marital status (married or living with a partner;
divorced, widowed, or separated; or never married), annual family income before the pandemic
(<$10 000, $10 000-$35 000, $35 000-$50 000, $50 000-$75 000, or >$75 000), health
insurance (private only, public only, private and public, or none), and employment status before the
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pandemic (employed as an essential worker or health care worker, employed as a nonessential
worker or non–health care worker, or not employed). Participants also provided information on
chronic conditions, location of their COVID-19 testing, and symptoms. Self-reports of symptoms
suggestive of COVID-19 were assessed using questions derived from the Centers for Disease Control
and Prevention Person Under Investigation for SARS-CoV-2 survey.13 Self-reported race and ethnicity
data from the Person Under Investigation survey were included because SARS-CoV-2 infection,
testing, and outcomes have been reported to vary across racial and ethnic groups.14

Patient-Reported Outcomes
The baseline and 3-month surveys included questions from the PROMIS-29 and the PROMIS SF-CF
8a.15 The PROMIS instruments use T score measurement, in which a score of 50 represents the mean
score of a reference population (ie, the US general population), with an SD of 10.11,16 For PROMIS
measures, higher scores correspond to a greater degree of the outcome being measured (eg, greater
fatigue). The T score was used to measure outcomes for 7 of the PROMIS-29 subscales (physical
function, anxiety, depression, fatigue, social participation,1 sleep disturbance, and pain interference)
and the PROMIS SF-CF 8a survey. A single-item numerical rating scale for pain intensity (“In the last
7 days, how would you rate your pain on average?”; score range, 0-10, with 0 indicating no pain and
10 indicating worst imaginable pain) is included in the PROMIS-29 survey. Due to a survey
specification clerical error, participants were incorrectly presented with the 4 response options for
the 9-item Public Health Questionnaire (ie, with 1 indicating not at all, 2 indicating several days, 3
indicating more than half of the days, and 4 indicating early every day) in place of the 5 response
options for the PROMIS-29 subdomain measuring the ability to participate in social roles and
activities (ie, with 1 indicating never, 2 indicating rarely, 3 indicating sometimes, 4 indicating usually,
and 5 indicating always). Therefore, to calculate the scaled T score for the social participation
domain, we conducted an equivalent score mapping correction after data collection, which resulted
in 4 possible scores (ie, with 1 indicating never, 2.33 indicating rarely, 3.67 indicating sometimes or
usually, and 5 indicating always).

Figure 1. INSPIRE Participant Flow Diagram
4256 Provided consent
1743 Excluded
1620 Incomplete enrollment
71 Ineligible
52 Withdrew
2513 Enrolled
4 Excluded because of incomplete
baseline survey
2509 Enrolled
1086 Excluded from analysis because
3-mo survey not yet due
1423 Enrolled
1006 With COVID-19
417 With no COVID-19
423 Nonresponders excluded
284 With COVID-19
139 With no COVID-19
1000 Analyzed

722 With COVID-19

278 With no COVID-19
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In addition to reporting scaled T scores for these measures, we applied previously defined
cutoffs to subscales to identify high levels of impairment.17 For physical function, social participation,
and cognitive function (for which higher scores are better), scores lower than 40 represent moderate
to severe impairment, and scores of 40 or higher represent normal to mild impairment. For anxiety,
depression, fatigue, sleep disturbance, and pain interference (for which lower scores are better),
scores lower than 60 represent normal to mild impairment, and scores of 60 or higher represent
moderate to severe impairment.
The T score cutoff for a clinically meaningful within-group change generally ranges between 2
and 6 points.18 Therefore, we interpreted changes in T scores of at least 2 points to represent
clinically meaningful changes in well-being measures across time points (with the exception of pain
intensity, for which clinically meaningful changes were represented by T score changes of ⱖ1
point19).

Statistical Analysis
Statistical analyses were performed using SAS software, version 9.4 (SAS Institute Inc). All tests were
2-sided with a significance threshold of P = .05. Sociodemographic and clinical characteristics of the
COVID-19 groups (COVID positive vs COVID negative) were compared using χ2 tests for categorical
variables and t tests for continuous variables. The frequency of missingness differed across
participant characteristics and ranged from 2 to 63 missing values. No systematic patterns in
missingness were observed; therefore, missingness at random was assumed. All percentages and P
values were calculated after excluding missing values.
Scaled scores on PROMIS measures were compared by COVID-19 status at both baseline and
3-month follow-up using t tests, and categorical thresholds for PROMIS subscales (eg, normal to mild
anxiety vs moderate to severe anxiety) were compared by COVID-19 status using χ2 tests. We
evaluated bivariate change measures (difference in PROMIS scores between baseline and 3-month
follow-up), comparing by COVID-19 status, using t tests. We used sequential multivariable linear
regression analysis to model changes in PROMIS scores; the regression coefficient for the difference
over time (baseline vs 3-month follow-up) by COVID-19 status (positive vs negative) was reported.
First, unadjusted estimates were calculated, followed by models adjusting for demographic
characteristics (including age and race), then social factors (including marital status, income,
employment, and health insurance), then health conditions (including asthma, hypertension, and
diabetes), then the baseline values of each PROMIS measure (eg, modeling change in physical
function as the outcome, adjusted for physical function at baseline). Each new model adjusted for
variables in addition to those included in the previous model (eg, social factors were added to the
previous model adjusted for demographic characteristics).
Because baseline symptoms varied between the COVID-19–positive and COVID-19–negative
groups, we performed a series of sensitivity analyses to evaluate the extent to which differences in
the initial severity of illness may impact observed differences by COVID-19 status. First, we stratified
our regression analyses based on initial COVID-19 testing location, comparing those who received
their COVID-19 test in an emergency department (ED) or hospital with those who used an at-home
test or received testing in an ambulatory setting (eg, a tent or drive-up site). We hypothesized that
those who received testing in an ED or hospital (regardless of COVID-19 status) would be more likely
to have experienced greater symptom severity. Second, because severity and outcomes have been
correlated with age, we stratified the analysis by age at baseline.

Results
Among 1000 participants included in the analysis, 722 (72.2%) had positive results for COVID-19, and
278 (27.8%) had negative results (Table 1). Of 998 participants at enrollment, 406 (40.7%) were
aged 18 to 34 years, 286 (28.7%) were aged 35 to 49 years, 215 (21.5%) were aged 50 to 64 years,
and 91 (9.1%) were 65 years and older. Among 972 participants, 644 (66.3%) identified as female. Of
JAMA Network Open. 2022;5(12):e2244486. doi:10.1001/jamanetworkopen.2022.44486 (Reprinted)
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Table 1. Sociodemographic and Clinical Characteristics of Adults With Symptomatic Illness Who Received Positive vs Negative COVID-19 Test Results at Enrollment
Participants, No./total No. (%)a
Total
(N = 1000)

Positive COVID-19 result
(n = 722)

Negative COVID-19 result
(n = 278)

18-34

406/998 (40.7)

288/721 (39.9)

118/277 (42.6)

35-49

286/998 (28.7)

220/721 (30.5)

66/277 (23.8)

50-64

215/998 (21.5)

160/721 (22.2)

55/277 (19.9)

≥65

91/998 (9.1)

53/721 (7.4)

38/277 (13.7)

Female

644/972 (66.3)

464/703 (66.0)

180/269 (66.9)

Male

313/972 (32.2)

232/703 (33.0)

81//269 (30.1)

Transgender, nonbinary, or other

15/972 (1.5)

7/703 (1.0)

8/269 (3.0)

Hispanic

151/984 (15.3)

110/712 (15.4)

41/272 (15.1)

Non-Hispanic

833/984 (84.7)

602/712 (84.6)

231/272 (84.9)

Characteristic

P value

Demographic characteristics
Age at enrollment, y

.005

Gender

.07b

Ethnicity
.88

Racec
Asian, Native Hawaiian, or other Pacific Islander

89/974 (9.1)

52/706 (7.4)

37/268 (13.8)

Black or African American

131/974 (13.4)

91/706 (12.9)

40/268 (14.9)

White

685/974 (70.3)

508/706 (72.0)

177/268 (66.0)

Other or multiple races

69/974 (7.1)

55/706 (7.8)

14/268 (5.2)

Less than high school diploma

17/966 (1.8)

13/700 (1.9)

4/266 (1.5)

High school or GED diploma

106/966 (11.0)

78/700 (11.1)

28/266 (10.5)

Some college but no degree

149/966 (15.4)

106/700 (15.1)

43/266 (16.2)

.007

Educational attainment

.70b

College degree
2y

87/966 (9.0)

65/700 (9.3)

22/266 (8.3)

4y

290/966 (30.0)

218/700 (31.1)

72/266 (27.1)

317/966 (32.8)

220/700 (31.4)

97/266 (36.5)

Married or living with a partner

503/977 (51.5)

383/706 (54.2)

120/271 (44.3)

Divorced, widowed, or separated

126/977 (12.9)

80/706 (11.3)

46/271 (17.0)

Never married

348/977 (35.6)

243/706 (34.4)

105/271 (38.7)

More than 4-y college degree
Marital status

.008

Annual family income before pandemic, $
<10 000

70/979 (7.2)

44/707 (6.2)

26/272 (9.6)

10 000-35 000

132/979 (13.5)

91/707 (12.9)

41/272 (15.1)

35 000-50 000

124/979 (12.7)

76/707 (10.7)

48/272 (17.6)

50 000-75 000

126/979 (12.9)

100/707 (14.1)

26/272 (9.6)

>75 000

483/979 (49.3)

369/707 (52.2)

114/272 (41.9)

Prefer not to answer

44/979 (4.5)

27/707 (3.8)

17/272 (6.3)

Private only

663/981 (67.6)

499/709 (70.4)

164/272 (60.3)

Private and public

42/981 (4.3)

25/709 (3.5)

17/272 (6.3)

Public only

240/981 (24.5)

155/709 (21.9)

85/272 (31.3)

None

36/981 (3.7)

30/709 (4.2)

6/272 (2.2)

Employed as essential worker or health care worker

409/978 (41.8)

309/707 (43.7)

100/271 (36.9)

Employed as nonessential worker or non–health care worker

373/978 (38.1)

270/707 (38.2)

103/271 (38.0)

Not employed

196/978 (20.0)

128/707 (18.1)

68/271 (25.1)

<.001

Health insurance

.001

Employment status before pandemic

.03

(continued)
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Table 1. Sociodemographic and Clinical Characteristics of Adults With Symptomatic Illness Who Received Positive vs Negative COVID-19 Test Results at Enrollment
(continued)
Participants, No./total No. (%)a
Characteristic

Total
(N = 1000)

Positive COVID-19 result
(n = 722)

Negative COVID-19 result
(n = 278)

144/993 (14.5)

101/715 (14.1)

43/278 (15.5)

P value

Clinical characteristics
Location of COVID-19 testing
Hospital
Emergency department

90/993 (9.1)

46/715 (6.4)

44/278 (15.8)

Clinic including an urgent care clinic

143/993 (14.4)

104/715 (14.5)

39/278 (14.0)

Tent or drive-up testing site

526/993 (53.0)

403/715 (56.4)

123/278 (44.2)

At-home testing kit

15/993 (1.5)

10/715 (1.4)

5/278 (1.8)

Other

75/993 (7.6)

51/715 (7.1)

24/278 (8.6)

<.001b

Hospitalization
Hospitalized

76/937 (8.1)

72/665 (10.8)

4/272 (1.5)

Not hospitalized

861/937 (91.9)

593/665 (89.2)

268/272 (98.5)

<.001

Preexisting conditions
Asthma (moderate or severe)

137/934 (14.7)

85/665 (12.8)

52/269 (19.3)

.01

Hypertension or high blood pressure

169/934 (18.1)

109/665 (16.4)

60/269(22.3)

.03

Diabetes

67/934 (7.2)

39/665 (5.9)

28/269 (10.4)

.01

Overweight or obesity

280/934 (30.0)

194/665 (29.2)

86/269 (32.0)

.40

Emphysema or COPD

22/934 (2.4)

12/665 (1.8)

10/269 (3.7)

.08

Heart conditiond

42/934 (4.5)

25/665 (3.8)

17/269 (6.3)

.10

Smokinge

49/934 (5.2)

38/665 (5.7)

11/269 (4.1)

.31

Kidney disease

14/934 (1.5)

8/665 (1.2)

6/269 (2.2)

.24b

Liver disease

17/934 (1.8)

11/665 (1.7)

6/269 (2.2)

.59b

Systemicf

780/1000 (78.0)

626/722 (86.7)

154/278 (55.4)

<.001

Musculoskeletalg

572/1000 (57.2)

466/722 (64.5)

106/278 (38.1)

<.001

HEENT

830/1000 (83.0)

657/722 (91.0)

173/278 (62.2)

<.001

Pulmonaryi

604/1000 (60.4)

490/722 (67.9)

114/278 (41.0)

<.001

Cardiovascularj

273/1000 (27.3)

224/722 (31.0)

49/278 (17.6)

<.001

Gastrointestinalk

366/1000 (36.6)

289/722 (40.0)

77/278 (27.7)

<.001

Other

115/983 (11.7)

98/711 (13.8)

17/272 (6.3)

.001

Reported symptoms at baseline

h

Abbreviations: COPD, chronic obstructive pulmonary disease; GED, general educational development; HEENT, head, ears, eyes, nose, and throat.
a

The frequency of missingness differed across participant characteristics and ranged from 2 to 63 missing values. No systematic patterns in missingness were observed; therefore,
missingness at random was assumed. All percentages and P values were calculated after excluding missing values.

b

For variables expected to have statistical significance of P < .05, P values were estimated using the Fisher exact method. Other P values were estimated using the χ2 test.

c

Participants self-reported their race according to the following categories: American Indian or Alaska Native; Asian, Native Hawaiian, or other Pacific Islander; Black or African
American; White; other race; or more than 1 race among the available categories.

d

Heart conditions included coronary artery disease, heart failure, and cardiomyopathy.

e

Smoking was defined as current smoking of any type of tobacco, including smokeless tobacco.

f

Systemic symptoms included having a fever higher than 38 °C (100.4 °F), feeling hot or feverish, chills, experiencing repeated shaking with chills, and feeling more tired than usual.

g

Musculoskeletal symptoms included muscle aches and joint pains.

h

HEENT symptoms included runny nose, sore throat, decrease or change in smell, decrease or change in taste, hair loss, and headache.

i

Pulmonary symptoms included new cough, worsening of chronic cough, shortness of breath, and wheezing.

j

Cardiovascular symptoms included pain or tightness in chest and palpitations.

k

Gastrointestinal symptoms included nausea or vomiting, abdominal pain, and diarrhea (>3 loose or looser than normal stools within 24 hours).

984 participants, 833 (84.7%) identified as non-Hispanic, and 685 (70.3%) identified as White. Most
participants were married or lived with a partner (503 of 977 individuals [51.5%]) and were privately
insured (663 of 981 individuals [67.6%]) .
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As shown in Table 1, compared with participants in the COVID-19–positive group, those in the
COVID-19–negative group were older and more likely to be of non-White race (eg, Black or African
American); be unmarried; have lower annual family income; have public insurance; be unemployed;
receive COVID-19 testing in an ED; and have a higher prevalence of moderate or severe asthma,
hypertension or high blood pressure, or diabetes. No differences between groups were observed in
the prevalence of the other 6 preexisting conditions (overweight or obesity, emphysema or chronic
obstructive pulmonary disease, heart conditions, smoking, kidney disease, and liver disease)
investigated in the univariate analyses. Participants in the COVID-19–positive group vs the COVID-19–
negative group reported more symptoms at baseline (eg, head, ears, eyes, nose, and throat
symptoms: 657 of 722 individuals [91.0%] vs 173 of 278 individuals [62.2%]) and were more likely to
have been hospitalized for their symptomatic illness (72 of 665 individuals [10.8%] vs 4 of 272
individuals [1.5%]).
To evaluate the potential for nonresponse bias, we evaluated baseline characteristics among
responders and nonresponders (ie, those unavailable for follow-up) to the 3-month survey (eTable 1
in Supplement 1). Compared with responders (n = 1000), nonresponders (n = 423) were more likely
to be older, identify as Black or African American, have lower educational attainment, have lower
income, be unemployed, receive their COVID-19 test in the ED or hospital, and report fewer
symptoms at baseline.
At baseline, participants in the COVID-19–positive group vs the COVID-19–negative group
reported less anxiety (mean [SD] score, 53.4 [10.0] vs 55.1 [10.6]; P = .02), depression (mean [SD]
score, 50.1 [9.1] vs 51.8 [9.8]; P = .01), pain interference (mean [SD] score, 50.5 [10.1] vs 53.0 [10.2];
P < .001), and pain intensity (mean [SD] score, 2.7 [2.7] vs 3.4 [2.8]; P < .001) (Table 2; Figure 2). In
the unadjusted analyses, 459 of 709 participants (64.7%) in the COVID-19–positive group vs 182 of
270 participants (67.4%) in the COVID-19–negative group (P = .43) reported moderate to severe
impairments across any PROMIS domain at baseline; 282 of 712 participants (39.6%) in the COVID19–positive group vs 147 of 275 participants (53.5%) in the COVID-19–negative group (P < .001)
reported moderate to severe impairments across any PROMIS domain at 3-month follow-up (eFigure
in Supplement 1). Overall, 156 of 712 participants (21.9%) in the COVID-19–positive group and 75 of
275 participants (27.3%) in the COVID-19–negative group experienced poor mental health (ie,
moderate to severe anxiety or depression) at 3-month follow-up.
Compared with participants in the COVID-19–negative group, those in the COVID-19–positive
group had better unadjusted improvements from baseline to 3-month follow-up for physical function
(mean [SD] difference in score from baseline to follow-up, 6.1 [9.8] vs 3.1 [9.2]; difference in mean
score between groups, 3.0; P < .001), fatigue (mean [SD] difference in score from baseline to
follow-up, −5.3 [9.9] vs −3.5 [8.8]; difference in mean score between groups, −1.8; P = .01), and social
participation (mean [SD] difference in score from baseline to follow-up, 6.1 [12.4] vs 2.8 [12.3];
difference in mean score between groups, 3.3; P < .001) (Table 2). After adjustment, differences in
measures of well-being between baseline and follow-up were statistically and clinically better among
those in the COVID-19–positive group vs the COVID-19–negative group with respect to social
participation (β = 3.32; 95% CI, 1.84-4.80; P < .001) (Table 3). Statistically significant differences in
score changes between groups were observed in other domains, but these differences were not
clinically meaningful.
Stratified sensitivity analyses revealed no significant or clinically meaningful differences in
PROMIS scores over time between those in the COVID-19–positive group vs those in the COVID-19–
negative group who received their COVID-19 test in the ED or hospital (ie, those who had more
severe initial presentation) (eTable 2 in Supplement 1). Significantly better changes over time in
several domains were observed among participants in the COVID-19–positive vs COVID-19–negative
group who received testing in an ambulatory setting (eg, social participation: β = 4.16 [95% CI,
2.12-6.20]; P < .001; cognitive function: β = 3.33 [95% CI, 1.45-5.22]; P < .001). Improvements in
PROMIS scores among participants in the COVID-19–positive vs COVID-19–negative group were
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concentrated among participants aged 18 to 34 years (eg, social participation: β = 3.90 [95% CI, 1.756.05]; P < .001; cognitive function: β = 2.91 [95% CI, 0.85-4.97]; P = .01), whereas participants 35
years and older experienced similar differences in PROMIS measures over time regardless of COVID19 status.

Discussion
In this cohort study, interim analysis of the first 1000 participants enrolled in a large, geographically
diverse study revealed that a substantial proportion of individuals with positive COVID-19 results
(39.6%) described moderate to severe decrements in their physical, mental, or social well-being at 3
months after symptomatic illness; however, these findings must be reviewed alongside similar
results among participants with negative COVID-19 results (53.5% with moderate to severe
decrements). Around the time of their acute illness, when compared with those who tested negative,
participants who tested positive reported similar or slightly better well-being. As both groups
progressed to 3 months after acute illness, participants in the COVID-19–positive group reported
greater overall changes in their social participation compared with participants in the COVID-19–

Table 2. Unadjusted Patient-Reported Outcome Measures at Baseline and 3-Month Follow-up
by COVID-19 Status at Baseline
PROMIS score, mean (SD)b
Total
(N = 1000)

Positive COVID-19
result (n = 722)

Negative COVID-19
result (n = 278)

P value

Cognitive function

46.3 (11.3)

46.5 (11.4)

45.7 (11.2)

.29

Physical function

45.2 (10.3)

45.0 (10.3)

45.8 (10.1)

.29

Social participation

49.2 (12.1)

49.3 (12.4)

49.1 (11.3)

.86

Anxiety

53.9 (10.2)

53.4 (10.0)

55.1 (10.6)

.02

Depression

50.6 (9.3)

50.1 (9.1)

51.8 (9.8)

.01

Fatigue

55.7 (10.1)

55.4 (10.4)

56.4 (9.4)

.16

Sleep disturbance

52.0 (5.1)

52.0 (5.3)

52.1 (4.7)

.74

Pain interference

51.2 (10.2)

50.5 (10.1)

53.0 (10.2)

<.001

Pain intensity

2.9 (2.7)

2.7 (2.7)

3.4 (2.8)

<.001

Cognitive function

48.2 (11.6)

48.9 (11.5)

46.4 (11.6)

.002

Physical function

50.5 (8.7)

51.2 (8.2)

48.8 (9.7)

<.001

Social participation

54.5 (11.3)

55.5 (11.0)

51.9 (11.7)

<.001

Anxiety

51.3 (10.1)

50.6 (9.8)

53.2 (10.5)

<.001

Depression

49.1 (9.2)

48.5 (8.9)

50.6 (9.7)

.001

Fatigue

50.8 (10.8)

50.0 (10.6)

53.0 (11.0)

<.001

Sleep disturbance

51.1 (4.8)

50.9 (4.7)

51.6 (4.8)

.04

Pain interference

48.2 (9.3)

47.3 (8.9)

50.3 (9.9)

<.001

Pain intensity

2.2 (2.5)

1.9 (2.4)

2.8 (2.7)

<.001

Cognitive function

1.9 (9.7)

2.2 (9.9)

0.9 (9.2)

.06

Physical function

5.2 (9.7)

6.1 (9.8)

3.1 (9.2)

<.001

Social participation

5.2 (12.5)

6.1 (12.4)

2.8 (12.3)

<.001

Anxiety

−2.4 (8.9)

−2.7 (9.1)

−1.8 (8.3)

.19

Depression

−1.4 (7.7)

−1.4 (7.7)

−1.1 (7.7)

.56

Fatigue

−4.8 (9.6)

−5.3 (9.9)

−3.5 (8.8)

.01

Sleep disturbance

−0.9 (5.2)

−1.0 (5.3)

−0.5 (5.2)

.19

Pain interference

−2.9 (9.0)

−3.0 (8.8)

−2.7 (9.5)

.67

Pain intensity

−0.7 (2.4)

−0.8 (2.3)

−0.6 (2.6)

.16

Outcomea
Baseline

Follow-up at 3 mo

Abbreviation: PROMIS, Patient-Reported Outcomes
Measurement Information System.
a

For physical function, social participation, and
cognitive function, lower scores (at baseline and
follow-up) were indicative of worse outcomes; for all
other domains, higher scores (at baseline and
follow-up) were indicative of worse outcomes. For
physical function, social participation, and cognitive
function, a positive difference in scores (between
baseline and follow-up) was indicative of
improvement; for all other measures, a negative
difference in scores (between baseline and
follow-up) was indicative of improvement. Pain
intensity (at baseline and follow-up) was scored from
0 (no pain) to 10 (worst imaginable pain). All other
measures (at baseline and follow-up) represent a
scaled T score, with a population-normed mean (SD)
of 50 (10) points. For pain intensity, a withinperson (ie, over time) difference of 1 or higher was
considered clinically meaningful; for all other
measures, an absolute difference of 2 or higher was
considered clinically meaningful.

b

Scores were based on responses to the 29-item
PROMIS survey (version 2.1) and the PROMIS Short
Form–Cognitive Function 8a survey.

Difference between baseline
and 3-mo follow-up
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negative group. These improvements were concentrated among those who were younger and those
who received testing in an ambulatory setting.
Notably, we recruited participants with acute symptoms suggestive of a first episode of
COVID-19 illness, including those with and without a positive result on a COVID-19 test, which
represented heterogeneous groups. The Centers for Disease Control and Prevention defines PCCs as

Figure 2. Scaled Scores on PROMIS Outcome Measures at Baseline and 3-Month Follow-up Among Participants
With Positive vs Negative COVID-19 Test Results
COVID-19 at baseline
COVID-19 at follow-up

Higher scores are better

58

No COVID-19 at baseline
No COVID-19 at follow-up

Lower scores are better

Mean PROMIS scaled T score

56
54
52
50
48
46
44
Cognitive
function

Physical
function

Social
participation

Anxiety

Depression

Fatigue

Sleep
disturbance

Pain
interference

Subscale

Scaled scores were based on responses to the 29-item
Patient-Reported Outcomes Measurement
Information System (PROMIS) survey (version 2.1) and
the PROMIS Short Form–Cognitive Function 8a survey.
Scores were not adjusted for demographic factors. For
each domain, the mean (SD) score in the US was 50
(10) points. For cognitive function, physical, function,
and social participation, higher scores are better; for all
other measures, lower scores are better. Hashed lines
between baseline and follow-up points indicate
changes that did not meet the within-group clinically
meaningful change of at least 2 points.

Table 3. Changes in Patient-Reported Outcome Scores Between Participants With vs Without Positive COVID-19 Test Results at Baseline
Change in score, β (95% CI)a,b
Adjusted models
Outcome

Unadjusted model

Demographic
characteristicsc

Social factorsd

Health conditionse

Cognitive function

1.63 (0.20 to 3.05)

1.65 (0.21 to 3.10)

1.74 (0.28 to 3.20)

1.78 (0.31 to 3.26)

1.94 (0.61 to 3.27)

Physical function

2.97 (1.56 to 4.38)

3.19 (1.76 to 4.62)

2.98 (1.54 to 4.42)

3.02 (1.57 to 4.48)

1.80 (0.72 to 2.87)

Baseline T scoresf,g

Social participation

3.82 (2.02 to 5.62)

3.91 (2.09 to 5.73)

3.68 (1.83 to 5.53)

3.59 (1.73 to 5.45)

3.32 (1.84 to 4.80)

Anxiety

−0.83 (−2.13 to 0.48)

−0.78 (−2.10 to 0.54)

−0.74 (−2.09 to 0.60)

−0.66 (−2.01 to 0.70)

−1.25 (−2.46 to −0.04)

Depression

−0.34 (−1.49 to 0.81)

−0.31 (−1.48 to 0.86)

−0.34 (−1.53 to 0.84)

−0.32 (−1.52 to 0.87)

−0.84 (−1.92 to 0.23)

Fatigue

−1.81 (−3.22 to −0.40)

−1.81 (−3.24 to −0.39)

−1.79 (−3.24 to −0.34)

−1.64 (−3.10 to −0.18)

−1.86 (−3.18 to −0.53)

Sleep disturbance

−0.68 (−1.46 to 0.09)

−0.74 (−1.53 to 0.04)

−0.86 (−1.66 to −0.07)

−0.79 (−1.58 to 0.01)

−0.65 (−1.29 to −0.01)

Pain interference

−0.25 (−1.60 to 1.11)

−0.33 (−1.70 to 1.04)

−0.33 (−1.72 to 1.06)

−0.38 (−1.78 to 1.02)

−1.35 (−2.48 to −0.23)

Pain intensity

−0.28 (−0.63 to 0.07)

−0.32 (−0.68 to 0.03)

−0.32 (−0.68 to 0.04)

−0.32 (−0.69 to 0.04)

−0.52 (−0.82 to −0.23)

Abbreviation: PROMIS, Patient-Reported Outcomes Measurement Information System.

d

Social factors included marital status, income, employment, and health insurance.

a

e

Health conditions included asthma, diabetes, and hypertension at 3-month follow-up.

f

Baseline T scores included the baseline value of each patient-reported outcome (eg,
individuals’ baseline scores for physical function).

g

Due to a survey specification clerical error, participants were incorrectly presented with
the 4 response options for the 9-item Public Health Questionnaire (ie, with 1 indicating
not at all, 2 indicating several days, 3 indicating more than half of the days, and 4
indicating early every day) in place of the 5 response options for the 29-item PROMIS
subdomain measuring ability to participate in social roles and activities (ie, with 1
indicating never, 2 indicating rarely, 3 indicating sometimes, 4 indicating usually, and 5
indicating always). We conducted an equivalent score mapping correction after data
collection, which resulted in 4 possible scores (ie, with 1 indicating never, 2.33
indicating rarely, 3.67 indicating sometimes or usually, and 5 indicating always) to
calculate the scaled T score.

b

c

Scores were based on responses to the 29-item PROMIS survey (version 2.1) and the
cognitive function domain on the PROMIS Short Form survey.
Coefficients for participants with positive vs negative COVID-19 test results (primary
exposure) are shown for all models; the difference in patient-reported outcomes (eg,
physical function) over time (baseline vs follow-up) was the primary outcome. For pain
intensity, a within-person (ie, over time) difference of 1 or higher was considered
clinically meaningful; for all other measures, an absolute difference of 2 or higher was
considered clinically meaningful. For physical function, social participation, and
cognitive function, a positive difference was indicative of greater improvement among
participants with positive vs negative COVID-19 test results; for all other measures, a
negative difference was indicative of greater improvement. In both cases, 95% CIs
inclusive of 0 indicated that differences over time for participants with positive vs
negative COVID-19 test results were statistically similar at P ⱖ .05.
Demographic characteristics included age and race.
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new, ongoing, or recurrent health problems more than 4 weeks after acute SARS-CoV-2 infection;
this definition is evolving and difficult to operationalize consistently across studies.13,20 The COVID19–positive group in the current study contained both those who had mostly recovered after initial
infection and those who might have had long COVID, for whom changes in well-being may have been
different. Therefore, all results should be interpreted to reflect a more general burden of SARSCoV-2 infection and the COVID-19 pandemic in addition to any specific burdens associated with
long COVID.
The greatest observed change in well-being among participants in the COVID-19–positive group
was for self-reported social participation. Given that the PROMIS subscale questions on social
participation assess individuals’ ability to engage in normal activities of life (eg, “I have trouble doing
all of my regular leisure activities with others”), this domain may be more salient than others when
considering whether someone feels like they have long COVID and may reflect the unique experience
of isolation and stigma that COVID-19–positive individuals may have endured. These findings suggest
that many COVID-19–positive individuals are able to achieve well-being scores that approach the US
average but do not imply that all patients with COVID-19 achieve well-being after illness. We found
that 39.6% of individuals in the COVID-19–positive group reported moderate to severe impairments
across any of the evaluated PROMIS well-being domains at follow-up. Future evaluations of post–
COVID-19 sequelae should assess key well-being domains, including social participation, in addition
to discrete symptoms, to fully capture the patient experience of long-term decrements in health and
well-being. Information on social participation may specifically help to identify COVID-19 experiences
for which more intense intervention and/or treatment may be required to return patients to their
previous activities of daily living.
Although other studies21-24 have found that those who recover from acute SARS-CoV-2
infection are at increased risk of an array of mental health disorders during the subsequent year,
participants in the current cohort experienced similar rates of depressive symptoms at baseline and
follow-up regardless of initial COVID-19 status. The presence and persistence of poor mental health
among nearly 1 in 4 participants (21.9% of the COVID-19–positive group and 27.3% of the COVID-19–
negative group) may reflect a more general pandemic exposure, which participants in both groups
experienced. The inclusion of a control group of participants who were exposed to the pandemic yet
tested negative and the use of validated scores with prepandemic population norms were important
to identifying broader pandemic impacts which may have had consequences for observed changes
in well-being. For instance, similarity in observed changes in both groups may be reflective of the
experience of being ill during a pandemic when access to care was hampered by pandemic
restrictions, potentially slowing recovery regardless of the cause of the underlying infection. These
broader pandemic societal impacts therefore call for increased attention to mental health services
irrespective of SARS-CoV-2 infection status.

Strengths and Limitations
This study has several strengths. These strengths include multicenter recruitment of patients from
diverse community, ambulatory, emergency, and inpatient settings; use of concurrent controls
through the recruitment of adults with symptomatic illness who tested negative for COVID-19; and
prospective data collection using validated scales.
This study also has several limitations. First, although this study aimed to recruit a diverse
population across the US, the requirement for access to a verifiable COVID-19 test, existing electronic
health record system, and internet-enabled devices to administer study components may have
biased the sample. Furthermore, those with the most severe disease may have been unable or
unwilling to participate; it is possible that those too ill to participate were at higher risk of
experiencing long-term symptoms after COVID-19. It is also possible that those with cognitive
impairment may have been less likely to enroll.
Second, it is unclear what heterogeneous acute condition (eg, bacterial pneumonia, respiratory
syncytial virus, or streptococcal pharyngitis) participants with symptomatic illness who tested
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negative may have been experiencing at the time of enrollment, making it difficult to hypothesize
whether COVID-19–negative participants would be expected to have more or less severe patientreported outcomes across time. Finding an appropriate comparison group for COVID-19–positive
participants is difficult, and comparison with participants with symptomatic illness who test negative
provides information on the ways in which infection with SARS-CoV-2 may differ from acute infection
with other viruses; however, comparison with this COVID-19–negative group may underestimate the
decrement in well-being compared with the general population who do not experience illness. There
are many potential comparison groups that could have been used as controls in this study (eg,
participants with asymptomatic illness who tested positive), and selection of a different comparator
group could have yielded different results.
Third, this analysis includes participants recruited through September 2021, so findings may not
be applicable to later infections involving subsequent SARS-CoV-2 variants. Fourth, COVID-19 tests
may yield false-negative or false-positive results25,26; therefore, we cannot exclude the possibility
that participants may have been misclassified (as having either a positive or negative COVID-19 test
result) based on their documented test result; this misclassification could explain part of the similar
change in well-being observed between the 2 groups. Fifth, our analyses only include data from
participants who completed both the baseline survey and the 3-month follow-up survey; 3-month
postbaseline assessment represents short-term observation of changes in well-being. Evaluating
longer-term changes might provide a better understanding of the range of well-being impacts that
those with COVID-19 experience.

Conclusions
In this cohort study, SARS-CoV-2 infection was not associated with worse physical, mental, and social
well-being (as measured through PROMIS scores) at 3-month follow-up compared with no SARSCoV-2 infection among adults with symptomatic illness. Adults with acute SARS-CoV-2 infection
reported substantial consequences for their well-being at baseline, with some clinically meaningful
improvements at 3-month follow-up; however, a high proportion of participants in the COVID-19–
positive group continued to report moderate to severe impairments in well-being at follow-up.
Improvements in reported social participation domains appeared to be more substantial among
participants in the COVID-19–positive group compared with the COVID-19–negative group and
among younger participants and those who received testing in an ambulatory setting. These findings
may reflect the impact of infection severity at presentation and emphasize the importance of
comparing COVID-19–positive participants with a concurrent control group of COVID-19–negative
participants as well as prepandemic population norms to identify the specific consequences of
infection with SARS-CoV-2 vs the broader consequences of the COVID-19 pandemic for patientreported outcomes.
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